Trivecta has a triple-taper femoral stem to fit a diverse range of patient anatomies, according to a news release. It also has sintered beads for initial and long-term stability, and Hydroxyapatite encourages biological fixation.
The implant will be available in the U.S. starting in the second quarter of 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
